



ANNOUNCEMENT

Taiwan Liposome Company and Ablynx entered into a Feasibility Study Agreement for Nanobody-Immunoliposome Development

Taipei, Taiwan – April 17, 2014 – Taiwan Liposome Company (TLC, 4152:TT) and Ablynx NV (ABLX) have entered into an agreement to research actively targeted nanoparticles for potential treatments across different indications combining TLC’s immunoliposome drug delivery platform with Ablynx’s Nanobody[®] targeting agents.

Immunoliposome combines TLC’s core technology of liposomal encapsulated drug delivery system (DDS) with Ablynx’s Nanobodies to deliver payloads intracellularly. Targeted immunoliposome nanoparticles will pass through leaky vasculatures of blood vessels and Nanobodies will target overexpressed receptors, resulting in receptor-complex internalization and subsequent intracellular release of over 10,000 payload molecules. This mechanism will enable the delivery of cytotoxic compound inside tumor cells for oncology indications, resulting in extensive tumor reduction through necrosis or apoptosis.

Dr. Keelung Hong, Chairman and CEO of TLC said: “TLC has been dedicated to the development of drug delivery systems since our establishment, and we are very excited to work with Ablynx in exploring the opportunity of bringing a more effective way of cancer treatment to benefit patients.”

George Yeh, President of TLC further commented: “Antibody drug conjugates brought much excitement to the healthcare industry by combining the targeting specificity of antibodies with the efficacy of cytotoxic compounds. Our immunoliposome platform can drastically enhance the therapeutic value by carrying a much higher payload amount. This collaboration with Ablynx marks the starting point of infinite development possibilities for this technology platform.”

TLC has successfully applied its liposomal drug delivery systems to oncology compounds including doxorubicin and vinca alkaloids. Ligands such as antibodies, Fabs, scFvs, proteins/peptides can all be used to achieve the targeting effect.

#####

About TLC

Taiwan Liposome Company is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic



conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications. TLC also has a team of researchers, management, production experts, and advisors who are building the company into an organization recognized for its excellence in targeted delivery and rapid advancement of products. TLC currently operates from Headquarter in Taipei (Taiwan), and subsidiary offices in South San Francisco (US) and Leiden (The Netherlands). For more information, please visit www.tlcbio.com

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

Media Contact for TLC:

Paggy Liou

t: +886 2 2655 7377 ext. 105

e: paggy@tlcbio.com

Media Contact for Ablynx:

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch

Associate Director Investor Relations

t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

 [@AblynxABLX](https://twitter.com/AblynxABLX)